Search

Zentalis Pharmaceuticals Inc

Lezárt

3.66 0.27

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.58

Maximum

3.8

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+138.65% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

20M

351M

Előző nyitás

3.39

Előző zárás

3.66

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 18. 23:56 UTC

Correlated Moves

Hecla Mining Co shares are lower in after-market trading, pressured by declining silver prices and rising sovereign bond yields amid inflation concerns.

2026. aug. 18. 23:56 UTC

Huntington Ingalls Industries shares are higher in after-market trading, reflecting strength above its 20-day moving average and near the upper end of its one-month range.

2026. aug. 18. 23:56 UTC

News

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

2026. aug. 18. 23:56 UTC

American Water Works shares are higher in after-market trading, despite rising sovereign bond yields impacting investor sentiment across equities.

2026. aug. 18. 23:56 UTC

Coursera Inc shares are higher in after-market trading, despite no specific news driving the movement. Broader market conditions reflect rising sovereign bond yields.

2026. aug. 18. 23:56 UTC

Correlated Moves
Social Media

The iShares Core U.S. Aggregate Bond ETF rose slightly in after-market trading, reflecting recent fluctuations in the 10-year yield and broader market sentiment.

2026. aug. 18. 23:56 UTC

Steel Dynamics Inc shares are trading lower in after-market hours, remaining below the 20-day moving average amid ongoing market weakness. No specific news was identified.

2026. aug. 18. 23:56 UTC

Chipotle Mexican Grill Inc shares are higher in after-market trading, reflecting a modest increase since Tuesday's close amid rising sovereign bond yields.

2026. aug. 18. 23:56 UTC

Array Technologies Inc shares are higher in after-market trading, reflecting a modest gain since Tuesday's close. The stock remains below its 20-day moving average.

2026. aug. 18. 23:56 UTC

News

Carvana Co's shares are higher in after-market trading amid concerns over major shareholder Mark Walter's federal investigation and potential stake sale valued at $2 billion.

2026. aug. 18. 23:56 UTC

Correlated Moves

Vicor Corp shares are lower in after-hours trading amid broader market volatility and concerns over rising bond yields and geopolitical tensions.

2026. aug. 18. 23:56 UTC

VF Corp shares are higher in after-market trading following a recovery from an earlier decline. The price remains below its 20-day moving average.

2026. aug. 18. 23:56 UTC

Fastenal Co shares are higher in after-market trading, maintaining performance above the 20-day moving average despite concerns over rising sovereign bond yields.

2026. aug. 18. 23:56 UTC

Paccar Inc shares rose in after-market trading, despite no specific news. The stock remains below its 20-day moving average amid broader market pressures.

2026. aug. 18. 23:56 UTC

Correlated Moves

Morgan Stanley shares are lower in after-market trading amid unusual volatility and rising bond yields, which are pressuring equities and growth prospects.

2026. aug. 18. 23:56 UTC

Social Media

Johnson & Johnson returns the C-CAR039 program to AbelZeta, while discussions about a potential acquisition of Legend Biotech continue. Shares are roughly flat in after-market trading.

2026. aug. 18. 23:56 UTC

Correlated Moves

Campbell Soup Co shares are higher in after-market trading, advancing since Tuesday's close and positioning above the 20-day moving average.

2026. aug. 18. 23:56 UTC

Upbound Group Inc shares are higher in after-market hours, recovering from three consecutive lower closes, though still below the 20-day moving average.

2026. aug. 18. 23:56 UTC

CEVA Inc. shares gained in after-market trading, reaching a high above Tuesday's close, though they remain below their 20-day moving average.

2026. aug. 18. 23:56 UTC

Coca-Cola Co's shares are higher in after-market trading, reflecting a modest increase since Tuesday's close. The stock remains above its 20-day moving average.

2026. aug. 18. 23:52 UTC

News
Social Media

IONQ partners with CMC Microsystems to enhance cloud quantum computing access in Canada. Shares are lower in after-market hours following the announcement.

2026. aug. 18. 23:51 UTC

Agilent Technologies Inc shares declined in after-market hours amid broader market concerns over rising bond yields and inflation linked to geopolitical tensions.

2026. aug. 18. 23:51 UTC

Genpact Ltd shares are lower in after-market hours amid concerns over elevated bond yields and inflation, despite initial gains earlier in the session.

2026. aug. 18. 23:51 UTC

Northrop Grumman shares are higher in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

2026. aug. 18. 23:51 UTC

Correlated Moves

Lennox International Inc shares are higher in after-market trading, reflecting broader trends in correlated assets like Toll Brothers Inc amid rising bond yields.

2026. aug. 18. 23:51 UTC

Correlated Moves

Pultegroup Inc shares are lower in after-market hours, following declines in the Russell 2000 Index and rising concerns over elevated bond yields.

2026. aug. 18. 23:51 UTC

Correlated Moves

Ichor Holdings Ltd shares are lower in after-market hours, influenced by a decline in the Nasdaq 100 Index and rising bond yields.

2026. aug. 18. 23:51 UTC

Monday.Com Ltd. shares declined after-market amid concerns over rising bond yields and inflation. The stock remains above its 20-day moving average.

2026. aug. 18. 23:51 UTC

Cardinal Health Inc. shares are lower in after-market trading, maintaining declines amid broader market concerns over elevated bond yields and inflation linked to geopolitical tensions.

2026. aug. 18. 23:51 UTC

Correlated Moves

Lam Research shares declined in after-market trading, influenced by rising bond yields and broader market trends, including a slight drop in the Nasdaq 100 Index.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

138.65% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.83 USD  138.65%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat